Abbott Laboratories (ABT) is a publicly traded Healthcare sector company. As of May 20, 2026, ABT trades at $88.47 with a market cap of $153.12B and a P/E ratio of 24.68. ABT moved -0.53% today. Year to date, ABT is -28.48%; over the trailing twelve months it is -34.47%. Its 52-week range spans $81.97 to $141.23. Analyst consensus is strong buy with an average price target of $120.24. Rallies surfaces ABT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Abbott’s Dividend Yield Hits Near-Decade High, Attracts Income Investors: Abbott’s annual dividend has held steady while shares have dipped, pushing its dividend yield to the highest level in nearly ten years and creating an unusually attractive income opportunity. The yield spike follows a modest price pullback with core growth forecasts remaining intact.
| Metric | Value |
|---|---|
| Price | $88.47 |
| Market Cap | $153.12B |
| P/E Ratio | 24.68 |
| EPS | $3.59 |
| Dividend Yield | 0.63% |
| 52-Week High | $141.23 |
| 52-Week Low | $81.97 |
| Volume | 5.95M |
| Avg Volume | 0 |
| Revenue (TTM) | $45.13B |
| Net Income | $6.28B |
| Gross Margin | 56.26% |
20 analysts cover ABT: 0 strong buy, 16 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $120.24.